x

Posted 18 August, 2023

POLARITYTE, INC. appointed new CEO

CEO Change detected for ticker OTC:PTEIQ in a 8-K filed on 18 August, 2023.


  On August 18, 2023, the Board of Directors (the "Board") of the Company appointed Richard Hague, who currently serves as the Chief Executive Officer of the Company, to serve as a director effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of POLARITYTE, INC.
Health Care/Life Sciences • Pharmaceuticals
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.
Market Cap
$737K
View Company Details
POLARITYTE, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Resignation of Chief Financial Officer


On August 18, 2023, Jacob Patterson, Chief Financial Officer of RegenETP, Inc. (formerly known as PolarityTE, Inc.), a Delaware corporation (the "Company"), informed the Company of his decision to resign effective immediately in order to pursue other opportunities.


Appointment of Director


On August 18, 2023, the Board of Directors (the "Board") of the Company appointed Richard Hague, who currently serves as the Chief Executive Officer of the Company, to serve as a director effective immediately. Mr. Hague will continue to serve as Chief Executive Officer of the Company.


There are no arrangements or understandings between Mr. Hague and any other person pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Hague and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr. Hague and the Company.


Resignation of Directors


On August 18, 2023, Willie C. Bogan, Peter A. Cohen, and David Seaburg resigned as members of the Board effective immediately, including as a member of all Board committees of which they are a member. The resignations of such directors was not due to any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices. At the time of their resignations, Mr. Bogan served on the Compensation Committee and the Nominating and Governance Committee (including as chairperson); and Mr. Cohen served on the Audit Committee and the Compensation Committee (including as chairperson) of the Board.